ArticleDiabetes care2022
Adherence to the American Diabetes Association's Glycemic Goals in the Treatment of Diabetes Among Older Americans, 2001-2018.
Article in Diabetes care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review.Molecules (Basel, Switzerland) · 2026Pooled it
- The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).Diabetes care · 2024 · on this mapTrial
- Effects of Ginkgo biloba extract on glycemic control, inflammatory markers, lipid profile, anthropometric indices, and safety parameters in patients with metabolic syndrome and type 2 diabetes: a meta-analysis.Diabetology & metabolic syndrome · 2026Review
- Epigallocatechin gallate prevents and alleviates type 2 diabetes mellitus (T2DM) through gut microbiota and multi-organ interactions in Wistar healthy rats and GK T2DM rats.Journal of advanced research · 2026Article
- 13. Older Adults: Standards of Care in Diabetes-2026.Diabetes care · 2026Review
- Duodenal Laser Ablation for Treatment of Type 2 Diabetes: Results of First in Human Study.United European gastroenterology journal · 2025Article
- 13. Older Adults: Standards of Care in Diabetes-2025.Diabetes care · 2025Review
- Crossing the deintensification chasm for older adults with diabetes.Journal of the American Geriatrics Society · 2024Article
- Treatment adherence: A Concept Analysis Using the Walker & Avant Method.Patient preference and adherence · 2024Review
- 13. Older Adults: Standards of Care in Diabetes-2024.Diabetes care · 2024Review
- A National Physician Survey of Deintensifying Diabetes Medications for Older Adults With Type 2 Diabetes.Diabetes care · 2023Article
- Time trends (2012-2020) in glycated hemoglobin and adherence to the glycemic targets recommended for elderly patients by the Japan Diabetes Society/Japan Geriatrics Society Joint Committee among memory clinic patients with diabetes mellitus.Journal of diabetes investigation · 2022Article
- Individualized Glycemic Goals for Older Adults Are a Moving Target.Diabetes care · 2022Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo assess trends in HbA1c and appropriateness of diabetes medication use by patient health status. RESEARCH DESIGN AND
methodsWe conducted cross-sectional analysis of 2001-2018 National Health and Nutrition Examination Survey (NHANES). We included older adults age ≥65 years who had ever been told they had diabetes, had HbA1c >6.4%, or had fasting plasma glucose >125 mg/dL. Health status was categorized as good, intermediate, or poor. Being below goal was defined as taking medication despite having HbA1c ≥1% below the glycemic goals of the American Diabetes Association (ADA), which varied by patient health status and time period. Drugs associated with hypoglycemia included sulfonylureas, insulin, and meglitinides.
resultsWe included 3,539 patients. Mean HbA1c increased over time and did not differ by health status. Medication use increased from 59% to 74% with metformin being the most common drug in patients with good or intermediate health and sulfonylureas and insulin most often prescribed to patients with poor health. Among patients taking medications, prevalence of patients below goal increased while prevalence of those above goal decreased from 2001 to 2018. One-half of patients with poor health and taking medications had below-goal HbA1c; two-thirds received drugs associated with hypoglycemia. Patients with poor health who were below goal had 4.9 (95% CI 2.3-10.4) times the adjusted odds of receiving drugs associated with hypoglycemia than healthy patients.
conclusionsIn accordance with ADA's newer Standards of Medical Care in Diabetes, HbA1c goals were relaxed but did not differ by health status. Below-goal HbA1c was common among patients with poor health; many were prescribed medications associated with a higher risk of hypoglycemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.